Therapeutic options in mantle cell lymphoma

被引：21

作者：

Gill, Saar ^{[1
]}

Ritchie, David ^{[1
,2
,3
]}

机构：

[1] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic 3001, Australia

[2] Univ Melbourne, Royal Melbourne Hosp, Dept Clin Haematol, Melbourne, Vic 3050, Australia

[3] Univ Melbourne, Royal Melbourne Hosp, Bone Marrow Transplant Serv, Melbourne, Vic 3050, Australia

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 03期

关键词：

lymphoma and Hodgkin disease; clinical results; chemotherapeutic approaches;

D O I：

10.1080/10428190701851364

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mantle cell lymphoma (MCL) is an aggressive lymphoma requiring intensive chemotherapy +/- autologous stem cell transplantation (SCT) to achieve optimal rates of progression-free survival. Here we review the treatment options for patients with newly-diagnosed or relapsed MCL and discuss recent advances in management, including the role of autologous and allogeneic SCT.

引用

页码：398 / 409

页数：12

共 76 条

[1] Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant [J].

Andersen, NS ;

Pedersen, L ;

Elonen, E ;

Johnson, A ;

Kolstad, A ;

Franssila, K ;

Langholm, R ;

Ralfkiær, E ;

Åkerman, M ;

Eriksson, M ;

Kuittinen, O ;

Geisler, CH .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (02) :73-80

[2] A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors [J].

Andersen, NS ;

Jensen, MK ;

Brown, PD ;

Geisler, CH .

EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) :401-408

[3] New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].

Armitage, JO ;

Weisenburger, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795

[4] Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT lymphoma working party. [J].

Avivi, Irit ;

Canals, Carme ;

Taghipour, Goli ;

Finke, Jurgen ;

Volin, Liisa ;

Beguin, Yves ;

Boogaerts, Marc ;

Crawley, Charles ;

Rieger, Michael ;

Schmitz, Norbert ;

Kobbe, Guido ;

Milligan, Donald ;

Niederwieser, Dietger W. ;

Russell, Nigel H. ;

Schwerdtfeger, Rainer ;

Sureda, Anna .

BLOOD, 2006, 108 (11) :890A-891A

[5] Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma [J].

Bauwens, D ;

Maerevoet, M ;

Michaux, L ;

Théate, I ;

Hagemeijer, A ;

Stul, M ;

Danse, E ;

Costantini, S ;

Vannuffel, P ;

Straetmans, N ;

Vekemans, MC ;

Deneys, V ;

Ferrant, A ;

Van Den Neste, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (03) :338-340

[6] A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150 [J].

Belch, A. ;

Kouroukis, C. T. ;

Crump, M. ;

Sehn, L. ;

Gascoyne, R. D. ;

Klasa, R. ;

Powers, J. ;

Wright, J. ;

Eisenhauer, E. A. .

ANNALS OF ONCOLOGY, 2007, 18 (01) :116-121

[7]

Bertini M, 1998, HAEMATOLOGICA, V83, P312

[8]

Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO

[9]

2-Z

[10]

Campo E, 1999, SEMIN HEMATOL, V36, P115

← 1 2 3 4 5 6 7 8 →